The 2024 Nobel Prize in Chemistry recognized groundbreaking work in computational protein design and protein structure prediction. Brian Kuhlman, PhD, made significant contributions to this work while a postdoctoral researcher in the Baker lab.
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, share their concerns about a growing reliance on industry-sponsored cancer clinical trials in the U.S.
Blake Rushing, PhD, will support the development of the Human Cancer Metabolome Atlas. The project aims to map the complex metabolic processes that drive cancer’s progression and resistance to treatment.
Lindsey James, PhD, and colleagues have developed a promising new compound that selectively and effectively breaks down a protein linked to various cancers, including multiple myeloma and prostate cancer.
NIH Director Monica Bertagnolli, MD, wrote about research led by UNC Lineberger’s Channing Der, PhD, and Adrienne Cox, PhD, that provided the most comprehensive molecular portrait of the workings of KRAS.
The UNC RNA Discovery Center held its inaugural retreat to bring together its members and trainees to present and discuss RNA science being conducted across UNC-Chapel Hill and beyond.
UNC Lineberger researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene, and how its activities impact pancreatic cancer outcomes.
UNC and UNC Lineberger researchers and trainees will be presenting talks and participating in scientific and educational panels and discussions on the latest cancer research at the ASCO Annual Meeting.
For Siddharth Sheth, DO, MPH, he knew UNC was the place for him when he pursued his first faculty position in medicine. However, it wasn’t just UNC that shaped his medical career. When Sheth’s mom was diagnosed with cancer and later relapsed, he knew oncology was the right path for him.
UNC Lineberger researchers have developed a molecule that is much more effective than a previously identified molecule at activating a biological pathway and spurring a strong anti-cancer immune response in preclinical studies.
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2023 Highly Cited Researchers™ list, which recognized scientists who published papers that ranked in the top 1% of cited publications in their field between 2012-2022.